Asia · Regional markets · The Financial Express

Nearly a quarter of cancer drugs see no price cut in latest NPPA review, study finds

Published by The Financial Express · India 10 h ago

A study reveals 24.7% of anti-cancer drugs saw no price drop under NPPA's trade margin rationalisation, as expensive MNC brands retained earlier MRPs.

Read the full article on The Financial Express Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.financialexpress.com)

Also worth reading

CNBC-TV18

Tech rout drives gold to one-year low, white metals sink deep into oversold zone

Mint

Nearly a quarter of cancer drugs see no price cut in latest NPPA review, study finds

Share

Also worth reading

Tech rout drives gold to one-year low, white metals sink deep into oversold zone

Nasdaq 100 Hits Third Correction of 2026 on Unwinding Tech Stock Bets

Global tech giants' spending spooks investors and drives bonds rally

Containing the Binance hack hinges on vow to make traders whole

Lawmakers to review draft law aimed at combating cross-border corruption

Accumulate Blue Star; target of Rs 1783: Prabhudas Lilladher